Terminated PHASE1 INTERVENTIONAL NCT00005787

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Ex Vivo Expanded Peripheral Blood Mononuclear Cells for the Elimination of Neutropenia Associated With High Dose Chemotherapy

Sponsor: National Cancer Institute (NCI)

Conditions Lymphoma Neutropenia

Interventions epoetin alfa filgrastim in vitro-treated peripheral blood stem cell transplantation recombinant flt3 ligand recombinant interleukin-3 sargramostim

Updated 5 times since 2017 Last updated: May 31, 2012 Started: Sep 30, 1999 Primary completion: Jan 31, 2002 Completion: Jan 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Per PI due to poor/inadequate accrual.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Lymphoma trials with similar outcome

Browse all Lymphoma trials

This PHASE1 trial investigates Lymphoma and Neutropenia and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Sep 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States